Drug Trial Radar · NCT01785875
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Last checked: Nov 20, 2026Latest source record: Apr 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
891
Actual
Start
Jul 31, 2013
Primary completion
Jul 1, 2015
Study completion Jul 1, 2015
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to describe the long-term safety and efficacy of etelcalcetide (AMG 416) for the treatment of SHPT in adults with CKD on hemodialysis.
Conditions
- Hyperparathyroidism, Secondary
Interventions
EtelcalcetideDrug
Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: From first dose until 30 days after last dose; the treatment period was 52 weeks.
- Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4Time frame: 52 weeks
- Number of Participants Who Developed Anti-etelcalcetide AntibodiesTime frame: Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit
- Change From Baseline in Blood PressureTime frame: Baseline and Weeks 24 and 48
Locations
208 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Pine Bluff, Arkansas
Research Site
Azusa, California
Research Site
Bakersfield, California
Research Site
Chula Vista, California
Research Site
Cudahy, California
Research Site
Fairfield, California
Research Site
Glendale, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Lynwood, California
Research Site
Northridge, California
Research Site
Norwalk, California
Research Site
Ontario, California
Research Site
Riverside, California
Research Site
San Gabriel, California
Research Site
Simi Valley, California
Research Site
Whittier, California
Research Site
Arvada, Colorado
Research Site
Denver, Colorado
Research Site
Stamford, Connecticut
Research Site
Coral Springs, Florida
Research Site
Lauderdale Lakes, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Pembroke Pines, Florida
Research Site
Pinecrest, Florida
Research Site
Tampa, Florida
Research Site
Augusta, Georgia
Research Site
Macon, Georgia
Research Site
Meridian, Idaho
Research Site
Evanston, Illinois
Research Site
Gurnee, Illinois
Research Site
Merrillville, Indiana
Research Site
Michigan City, Indiana
Research Site
Wichita, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Lafayette, Louisiana
Showing 40 of 208 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.